登录 注册 会员服务 联系我们

Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism

  • Published:2020 Issue:3.4 Volume:67 Page:343-350
  • ISSN:1343-1420
  • Container-title:The Journal of Medical Investigation
  • language:en
  • Short-container-title:J. Med. Invest.

Author:

Arai Sachiko1,Takeuchi Shinji12,Fukuda Koji12,Tanimoto Azusa1,Nishiyama Akihiro1,Konishi Hiroaki3,Takagi Akimitsu3,Takahashi Hiroyuki4,Ong S. Tiong5678,Yano Seiji12

Affiliation:

1. Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan

2. Nano Life Science Institute, Kanazawa University, Kanazawa, Japan

3. Yakult Central Institute, Yakult Honsha Co., Ltd., Kunitachi, Tokyo, Japan

4. Pharmaceutical business division, Yakult Honsha Co., Ltd., Tokyo, Japan

5. Cancer and Stem Cell Biology Signature Research Program, Duke-NUS Medical School, Singapore

6. Department of Haematology, Singapore General Hospital, Singapore

7. Department of Medical Oncology, National Cancer Centre Singapore, Singapore

8. Department of Medicine, Duke University Medical Center, Durham, NC, United States of America

Publisher

University of Tokushima Faculty of Medicine

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference32 articles.

1. 1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T ; North-East Japan Study Group : Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362 : 2380-2388, 2010

2. 2. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS ; FLAURA Investigators : Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378 : 113-125, 2018

3. 3. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J : A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141 : 69-80, 2010

4. 4. Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, Gómez HL, Baselga J, Arteaga CL, Rivera MN, Dias-Santagata D, Jain RK, Engelman JA : BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 1 : 352-365, 2011

5. 5. Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R : The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res 20 : 2001-2010, 2014

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3